Future developments in therapy

Carlos M Isales, Jay M. McDonald

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An exciting new era in bone biology is a result of our greater understanding not only of the mechanisms of action of the medications we currently use for treatment of osteoporosis but also of the molecular pathways involved in normal and abnormal bone formation. In the coming years our increased understanding of these molecular pathways will result in many new medications for osteoporosis therapy. Together with the development of new drugs it will be necessary to develop better ways of assessing bone quality. Since bone has both protein (collagen type I) and mineral (hydroxyapatite) components, both of which are essential to bone strength, measurements of bone mineral content by densitometry (DXA) will provide us with only a narrow perspective on the utility of the drug under development prior to full patient fracture studies. The information gathered from basic bone research must be used for the rational development of agents that increase bone strength within a narrow physiological window.

Original languageEnglish (US)
Pages (from-to)258-263
Number of pages6
JournalAnnals of the New York Academy of Sciences
Volume1117
DOIs
StatePublished - Jan 1 2007

Fingerprint

Bone
Bone and Bones
Osteoporosis
Therapeutics
Minerals
Densitometry
Durapatite
Collagen Type I
Osteogenesis
Pharmaceutical Preparations
Bone Density
Therapy
Research
Proteins

Keywords

  • Bisphosphonates
  • DKK-1
  • Sclerostin
  • TNF
  • TSH

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Future developments in therapy. / Isales, Carlos M; McDonald, Jay M.

In: Annals of the New York Academy of Sciences, Vol. 1117, 01.01.2007, p. 258-263.

Research output: Contribution to journalArticle

Isales, Carlos M ; McDonald, Jay M. / Future developments in therapy. In: Annals of the New York Academy of Sciences. 2007 ; Vol. 1117. pp. 258-263.
@article{35a0f1bda42b447aa3fef0db41a57a1e,
title = "Future developments in therapy",
abstract = "An exciting new era in bone biology is a result of our greater understanding not only of the mechanisms of action of the medications we currently use for treatment of osteoporosis but also of the molecular pathways involved in normal and abnormal bone formation. In the coming years our increased understanding of these molecular pathways will result in many new medications for osteoporosis therapy. Together with the development of new drugs it will be necessary to develop better ways of assessing bone quality. Since bone has both protein (collagen type I) and mineral (hydroxyapatite) components, both of which are essential to bone strength, measurements of bone mineral content by densitometry (DXA) will provide us with only a narrow perspective on the utility of the drug under development prior to full patient fracture studies. The information gathered from basic bone research must be used for the rational development of agents that increase bone strength within a narrow physiological window.",
keywords = "Bisphosphonates, DKK-1, Sclerostin, TNF, TSH",
author = "Isales, {Carlos M} and McDonald, {Jay M.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1196/annals.1402.000",
language = "English (US)",
volume = "1117",
pages = "258--263",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Future developments in therapy

AU - Isales, Carlos M

AU - McDonald, Jay M.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - An exciting new era in bone biology is a result of our greater understanding not only of the mechanisms of action of the medications we currently use for treatment of osteoporosis but also of the molecular pathways involved in normal and abnormal bone formation. In the coming years our increased understanding of these molecular pathways will result in many new medications for osteoporosis therapy. Together with the development of new drugs it will be necessary to develop better ways of assessing bone quality. Since bone has both protein (collagen type I) and mineral (hydroxyapatite) components, both of which are essential to bone strength, measurements of bone mineral content by densitometry (DXA) will provide us with only a narrow perspective on the utility of the drug under development prior to full patient fracture studies. The information gathered from basic bone research must be used for the rational development of agents that increase bone strength within a narrow physiological window.

AB - An exciting new era in bone biology is a result of our greater understanding not only of the mechanisms of action of the medications we currently use for treatment of osteoporosis but also of the molecular pathways involved in normal and abnormal bone formation. In the coming years our increased understanding of these molecular pathways will result in many new medications for osteoporosis therapy. Together with the development of new drugs it will be necessary to develop better ways of assessing bone quality. Since bone has both protein (collagen type I) and mineral (hydroxyapatite) components, both of which are essential to bone strength, measurements of bone mineral content by densitometry (DXA) will provide us with only a narrow perspective on the utility of the drug under development prior to full patient fracture studies. The information gathered from basic bone research must be used for the rational development of agents that increase bone strength within a narrow physiological window.

KW - Bisphosphonates

KW - DKK-1

KW - Sclerostin

KW - TNF

KW - TSH

UR - http://www.scopus.com/inward/record.url?scp=36549068757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549068757&partnerID=8YFLogxK

U2 - 10.1196/annals.1402.000

DO - 10.1196/annals.1402.000

M3 - Article

VL - 1117

SP - 258

EP - 263

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -